Genenta Science S.p.A.

Develops cell & gene therapies using engineered stem cells to treat solid tumors.

GNTA | NDAQ

Overview

Corporate Details

ISIN(s):: N/A
LEI:
Country:: United States of America
Address:: OLGETTINA, NO. 58, 20132 MILAN
Website:: https://www.genenta.com/
Sector:: Manufacturing
Industry:: Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Genenta Science S.p.A. is a clinical-stage immuno-oncology company developing proprietary cell and gene therapies for the treatment of solid tumors. The company's technology is centered on engineering a patient's own hematopoietic stem cells using a lentiviral vector to combat cancer. Its lead candidate, Temferon, is designed to make tumors visible to the immune system by reprogramming the tumor microenvironment and breaking immune tolerance. Genenta has completed a Phase 1 clinical trial in Glioblastoma Multiforme and has initiated a Phase 1/2a study in metastatic Renal Cell Carcinoma. The treatments are designed as one-time monotherapies that also have the potential to be used in combination to enhance the efficacy of other therapeutics, such as immune checkpoint inhibitors.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.

Quick Filters:

Filters

Filing Type

Language

Start date

End date

Clear

Bulk Actions:

	Date	Filing	Language	Size	Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Genenta Science S.p.A. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Genenta Science S.p.A.

This data is available as part of our premium data solutions. Contact our team for access.

Request This Data

Need More History? Access decades of standardized financials for Genenta Science S.p.A. via our API.

Get Historical Data →

Insider Transactions

Date	Insider Name	Position	Type	Shares	Value
No insider transactions recorded for this company.

Peer Companies

Company	Country	Ticker
Alpha Cognition Inc. Develops and commercializes novel treatments for neurodegenerative diseases like Alzheimer's and ALS.	United States of America	ACOG
Alteogen Inc. Biotech firm developing next-gen ADCs and biobetters with proprietary platform technologies.	South Korea	196170
ALTERITY THERAPEUTICS LTD Developing therapies for Parkinsonian disorders and MSA by inhibiting protein aggregation.	United States of America	ATHE
Alto Neuroscience, Inc. Developing precision medicines for depression and schizophrenia using a brain biomarker platform.	United States of America	ANRO
ALUMIS INC. Develops targeted oral therapies for immune-mediated diseases using precision immunology.	United States of America	ALMS
Alvotech Develops and manufactures affordable biosimilar medicines for patients worldwide.	United States of America	ALVO
Alvotech Holdings S.A Develops and manufactures affordable biosimilar medicines for global patient access.	Luxembourg	ALVO
ALX ONCOLOGY HOLDINGS INC Clinical-stage firm developing CD47 inhibitors for hematologic and solid tumors.	United States of America	ALXO
Alzamend Neuro, Inc. Developing lithium & vaccine therapies for neurodegenerative & psychiatric disorders.	United States of America	ALZN
Alzinova AB Developing targeted immunotherapies, including a vaccine, for Alzheimer's disease.	Sweden	ALZ